Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/32671
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDizdar, Oğuzhan Sıtkı-
dc.contributor.authorCoşkun, Banu Demet Özel-
dc.date.accessioned2023-05-16T07:07:45Z-
dc.date.available2023-05-16T07:07:45Z-
dc.date.issued2016-09-25-
dc.identifier.citationDizdar, O. S. vd. (2016). "Analysis of liver function test abnormalities in kidney transplant recipients: 7 year experience". Pakistan Journal of Medical Sciences, 32(6), 1330-1335.tr_TR
dc.identifier.issn1682-024X-
dc.identifier.urihttps://doi.org/10.12669/pjms.326.10725-
dc.identifier.urihttps://pjms.com.pk/index.php/pjms/article/view/10725-
dc.identifier.urihttp://hdl.handle.net/11452/32671-
dc.description.abstractObjective: Immunosuppressive drugs, antimicrobial agents and infectious complications may cause liver function test abnormalities (LFTA) in kidney transplant recipients (KTR). The objectives of this study were to identify the outcome of (LFTA). To identify the risk factors affecting development and severity of hepatotoxicity in KTR. Methods: We retrospectively evaluated the medical records of KTR. Hepatotoxicity attacks were defined as impairment in liver function tests that was responsive to drug dose reduction or discontinuation, or treatment of specific causes such as infectious complications. Results: One hundred-fifty-six episodes of hepatotoxicity occurred in 107 patients in 281 KTR, with an incidence of 38%. Patients with hepatotoxicity episodes had a high total mortality rate, higher incidence of positive pre-transplant cytomegalovirus (CMV) IgM test, higher creatinine values during the first month post-transplant, underwent additional acute rejection episodes, and received fewer cyclosporin A based ID. Only positive CMV IgM testing was identified as a significant independent risk factor for hepatotoxicity in our multiple analysis. Mycophenolatemofetil (MMF) related hepatotoxicity was the most common cause of drug related LFTA. Conclusions: Patients with LFTA can have significant complications. Pre-transplant positive CMV IgM tests predispose transplant recipients to the development of LFTA during the post-transplant period. MMF can be a serious hepatotoxic drug.en_US
dc.language.isoenen_US
dc.publisherProfessional Medical Publicationsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectGeneral & internal medicineen_US
dc.subjectComplicationen_US
dc.subjectCytomegalovirusen_US
dc.subjectHepatotoxicityen_US
dc.subjectMycophenolatemofetilen_US
dc.subjectKidney transplantationen_US
dc.subjectRenal-allograft recipientsen_US
dc.subjectGraft-rejectionen_US
dc.subjectCyclosporineen_US
dc.subjectSirolimusen_US
dc.subjectHepatotoxicityen_US
dc.subjectTacrolimusen_US
dc.subjectTherapyen_US
dc.subjectHepatitisen_US
dc.subjectDrugsen_US
dc.titleAnalysis of liver function test abnormalities in kidney transplant recipients: 7 year experienceen_US
dc.typeArticleen_US
dc.identifier.wos000390329600003tr_TR
dc.identifier.scopus2-s2.0-85007432951tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Nefroloji Bilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.identifier.startpage1330tr_TR
dc.identifier.endpage1335tr_TR
dc.identifier.volume32tr_TR
dc.identifier.issue6tr_TR
dc.relation.journalPakistan Journal of Medical Sciencesen_US
dc.contributor.buuauthorErsoy, Alparslan-
dc.contributor.buuauthorAksoy, Savaş-
dc.contributor.buuauthorYıldız, Abdülmecit-
dc.contributor.researcheridJ-1232-2013tr_TR
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.relation.collaborationSanayitr_TR
dc.identifier.pubmed28083020tr_TR
dc.subject.wosMedicine, general & internalen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ3en_US
dc.contributor.scopusid35612977100tr_TR
dc.contributor.scopusid57192690937tr_TR
dc.contributor.scopusid56256977500tr_TR
dc.subject.scopusLiver; Autoimmune Hepatitis; Infliximaben_US
dc.subject.emtreeAlanine aminotransferaseen_US
dc.subject.emtreeAlkaline phosphataseen_US
dc.subject.emtreeAntibiotic agenten_US
dc.subject.emtreeAspartate aminotransferaseen_US
dc.subject.emtreeAzathioprineen_US
dc.subject.emtreeCotrimoxazoleen_US
dc.subject.emtreeCreatinineen_US
dc.subject.emtreeCyclosporin Aen_US
dc.subject.emtreeCytokine receptor antagonisten_US
dc.subject.emtreeEverolimusen_US
dc.subject.emtreeGamma glutamyltransferaseen_US
dc.subject.emtreeImmunoglobulin Men_US
dc.subject.emtreeInterleukin 2 receptor antagonisten_US
dc.subject.emtreeLactate dehydrogenaseen_US
dc.subject.emtreeMycophenolate mofetilen_US
dc.subject.emtreePrednisoloneen_US
dc.subject.emtreeRapamycinen_US
dc.subject.emtreeTacrolimusen_US
dc.subject.emtreeUnclassified drugen_US
dc.subject.emtreeAcute graft rejectionen_US
dc.subject.emtreeAcute pancreatitisen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAlanine aminotransferase blood levelen_US
dc.subject.emtreeAlkaline phosphatase blood levelen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAspartate aminotransferase blood levelen_US
dc.subject.emtreeCholelithiasisen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCreatinine blood levelen_US
dc.subject.emtreeCytomegalovirusen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGamma glutamyl transferase blood levelen_US
dc.subject.emtreeGraft recipienten_US
dc.subject.emtreeHepatitis Ben_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHyperlipidemiaen_US
dc.subject.emtreeIncidenceen_US
dc.subject.emtreeKidney transplantationen_US
dc.subject.emtreeLactate dehydrogenase blood levelen_US
dc.subject.emtreeLiver function testen_US
dc.subject.emtreeLiver toxicityen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMortality rateen_US
dc.subject.emtreeObservational studyen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSepsisen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Ersoy_vd_2016_PDF.pdf279.65 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons